Format

Send to

Choose Destination
Expert Opin Emerg Drugs. 2015;20(4):625-36. doi: 10.1517/14728214.2015.1105215. Epub 2015 Nov 7.

New pharmacological treatment options for irritable bowel syndrome with constipation.

Author information

1
a Section of Digestive Diseases and Nutrition, Department of Medicine , Oklahoma University School of Medicine , 920 Stanton L. Young Blvd. WP 1345, Oklahoma City , OK 73104 , USA.

Abstract

INTRODUCTION:

Constipation predominant irritable bowel syndrome (IBS-C) is a common disorder and accounts for a large number of ambulatory visits. Sensory abnormalities, that is, presence of abdominal pain and discomfort, distinguish IBS-C from chronic idiopathic constipation.

AREA COVERED:

This review focuses on the pharmacology, efficacy, safety, and future of prucalopride, YKP-10811, DSP-6952, dexloxiglumide, linaclotide, plecanatide, tenapanor, and elobixibat.

EXPERT OPINION:

It is now well established that treatment focusing only on bowel transit provides incomplete relief to patients with IBS-C. Improved understanding of pathophysiology of IBS-C has led to use of sensory end points like complete spontaneous bowel movements and the FDA combined end point (abdominal pain and complete spontaneous bowel movements) in clinical trials. A number of drugs are in development and provide hope for this challenging group of patients. However, because of recent failures secondary to ineffectiveness and/or adverse events, we cautiously await how clinical data play out in larger studies and in clinical practice.

KEYWORDS:

DSP-6952; YKP-10811; bile acid transport inhibitor; cholecystokinin receptor antagonist; dexloxiglumide; elobixibat; guanylate cyclase-C agonist; linaclotide; plecanatide; serotonin agonist; sodium–proton exchange inhibitor; tenapanor

PMID:
26548544
DOI:
10.1517/14728214.2015.1105215
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center